EyePoint Pharmaceuticals constructs new cGMP manufacturing facility for the supply of EYP-1901 and YUTIQ.
The state-of-the-art cGMP manufacturing facility will be constructed in an area covering 40,000-square-foot. Moreover, the building consists of the capacity and capabilities to support commercial business and expanding pipeline.
This new facility provides significant manufacturing capacity to accelerate the clinical development and future commercial production for EYP-1901 and support the need for US FDA and China NMPA approved YUTIQ therapy.
The manufacturing facility will be dedicated for Good Manufacturing Practice (GMP) compliant to meet U.S. FDA and European Medicines Agency (EMA) standards and support EYP-1901’s clinical supply and commercial readiness upon regulatory approval.
The new construction is expected to be fully operational by the second half of 2024.